SAVA
Cassava Sciences, Inc.
Biotechnology
Market Cap$94M
5Y Perf.+539.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SAVA vs ATNM
Revenue, margins, valuation, and 5-year total return — side by side.
ATNM
Actinium Pharmaceuticals, Inc.
Biotechnology
Market Cap$38M
5Y Perf.-81.5%
SAVA vs ATNM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SAVA | ATNM |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $94M | $38M |
| Revenue (TTM) | $0.00 | $90K |
| Net Income (TTM) | $-106M | $-35M |
| Gross Margin | — | -8.1% |
| Operating Margin | — | -414.9% |
| Total Debt | $0.00 | $2M |
| Cash & Equiv. | $129M | $73M |
SAVA vs ATNM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SAVA
ATNM
| Stock | May 20 | Mar 26 | Return |
|---|---|---|---|
| Cassava Sciences, I… (SAVA) | 100 | 639.5 | +539.5% |
| Actinium Pharmaceut… (ATNM) | 100 | 18.5 | -81.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SAVA vs ATNM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ATNM leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Cassava Sciences, Inc. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
SAVA
Cassava Sciences, Inc.
The Income Pick
SAVA is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 1 yrs, beta 2.02
- EPS growth 77.6%
- -19.5% 10Y total return vs ATNM's -97.7%
Best for: income & stability and growth exposure
ATNM
Actinium Pharmaceuticals, Inc.
The Defensive Pick
ATNM carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 1.40, Low D/E 4.8%, current ratio 9.14x
- Beta 1.40, current ratio 9.14x
- -100.0% revenue growth vs SAVA's -5.4%
Best for: sleep-well-at-night and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ATNM | -100.0% revenue growth vs SAVA's -5.4% |
| Quality / Margins | SAVA | 5.4% margin vs ATNM's -384.4% |
| Stability / Safety | ATNM | Beta 1.40 vs SAVA's 2.02 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | SAVA | +25.3% vs ATNM's -12.9% |
| Efficiency (ROA) | ATNM | -52.3% ROA vs SAVA's -75.3% |
SAVA vs ATNM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2023
SAVA vs ATNM — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSAVALAGGINGATNM
ATNMActinium Pharmaceutic…
1leads
SAVACassava Sciences, Inc.
4leads
6 Total Categories
CATEGORYLEADERvs ATNMMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SAVA1/1
Valuation MetricsMultiples, price ratios, and targets
SAVA2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
SAVA6/6
Risk & VolatilityBeta, volatility, and downside exposure
ATNM2/2
Analyst OutlookRatings, price targets, and dividends
SAVA1/1
Income & Cash Flow (Last 12 Months)
SAVA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ATNM and SAVA operate at a comparable scale, with $90,000 and $0 in trailing revenue.
| Metric | SAVACassava Sciences,… | ATNMActinium Pharmace… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $90,000 |
| EBITDAEarnings before interest/tax | -$110M | -$37M |
| Net IncomeAfter-tax profit | -$106M | -$35M |
| Free Cash FlowCash after capex | -$84M | -$25M |
| Gross MarginGross profit ÷ Revenue | — | -8.1% |
| Operating MarginEBIT ÷ Revenue | — | -414.9% |
| Net MarginNet income ÷ Revenue | — | -384.4% |
| FCF MarginFCF ÷ Revenue | — | -278.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +62.1% | +56.8% |
SAVA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
SAVA leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | SAVACassava Sciences,… | ATNMActinium Pharmace… |
|---|---|---|
| Market CapShares × price | $94M | $38M |
| Enterprise ValueMkt cap + debt − cash | -$34M | -$33M |
| Trailing P/EPrice ÷ TTM EPS | -3.76x | -0.96x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.63x | 1.12x |
| Price / FCFMarket cap ÷ FCF | — | — |
SAVA leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
Evenly matched — SAVA and ATNM each lead in 3 of 6 comparable metrics.
Profitability & Efficiency
SAVA delivers a -95.8% return on equity — every $100 of shareholder capital generates $-96 in annual profit, vs $-152 for ATNM. On the Piotroski fundamental quality scale (0–9), ATNM scores 3/9 vs SAVA's 2/9, reflecting mixed financial health.
| Metric | SAVACassava Sciences,… | ATNMActinium Pharmace… |
|---|---|---|
| ROE (TTM)Return on equity | -95.8% | -151.7% |
| ROA (TTM)Return on assets | -75.3% | -52.3% |
| ROICReturn on invested capital | -6.3% | — |
| ROCEReturn on capital employed | -99.9% | -59.5% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 |
| Debt / EquityFinancial leverage | — | 0.05x |
| Net DebtTotal debt minus cash | -$129M | -$71M |
| Cash & Equiv.Liquid assets | $129M | $73M |
| Total DebtShort + long-term debt | $0 | $2M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Evenly matched — SAVA and ATNM each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
SAVA leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SAVA five years ago would be worth $3,302 today (with dividends reinvested), compared to $1,674 for ATNM. Over the past 12 months, SAVA leads with a +25.3% total return vs ATNM's -12.9%. The 3-year compound annual growth rate (CAGR) favors SAVA at -16.0% vs ATNM's -47.9% — a key indicator of consistent wealth creation.
| Metric | SAVACassava Sciences,… | ATNMActinium Pharmace… |
|---|---|---|
| YTD ReturnYear-to-date | -6.5% | -10.9% |
| 1-Year ReturnPast 12 months | +25.3% | -12.9% |
| 3-Year ReturnCumulative with dividends | -40.8% | -85.9% |
| 5-Year ReturnCumulative with dividends | -67.0% | -83.3% |
| 10-Year ReturnCumulative with dividends | -19.5% | -97.7% |
| CAGR (3Y)Annualised 3-year return | -16.0% | -47.9% |
SAVA leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
ATNM leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ATNM is the less volatile stock with a 1.40 beta — it tends to amplify market swings less than SAVA's 2.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ATNM currently trades 62.6% from its 52-week high vs SAVA's 39.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SAVACassava Sciences,… | ATNMActinium Pharmace… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.02x | 1.40x |
| 52-Week HighHighest price in past year | $4.98 | $1.95 |
| 52-Week LowLowest price in past year | $1.51 | $0.95 |
| % of 52W HighCurrent price vs 52-week peak | +39.3% | +62.6% |
| RSI (14)Momentum oscillator 0–100 | 46.8 | 52.8 |
| Avg Volume (50D)Average daily shares traded | 712K | 184K |
ATNM leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
SAVA leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
| Metric | SAVACassava Sciences,… | ATNMActinium Pharmace… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | 12 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
SAVA leads this category, winning 1 of 1 comparable metric.
Key Takeaway
SAVA leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). ATNM leads in 1 (Risk & Volatility). 1 tied.
Best OverallCassava Sciences, Inc. (SAVA)Leads 4 of 6 categories
Loading custom metrics...
SAVA vs ATNM: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SAVA or ATNM a better buy right now?
Analysts rate Cassava Sciences, Inc.
(SAVA) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SAVA or ATNM?
Over the past 5 years, Cassava Sciences, Inc.
(SAVA) delivered a total return of -67. 0%, compared to -83. 3% for Actinium Pharmaceuticals, Inc. (ATNM). Over 10 years, the gap is even starker: SAVA returned -19. 5% versus ATNM's -97. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SAVA or ATNM?
By beta (market sensitivity over 5 years), Actinium Pharmaceuticals, Inc.
(ATNM) is the lower-risk stock at 1. 40β versus Cassava Sciences, Inc. 's 2. 02β — meaning SAVA is approximately 44% more volatile than ATNM relative to the S&P 500.
04Which is growing faster — SAVA or ATNM?
On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc.
grew EPS 77. 6% year-over-year, compared to 30. 6% for Actinium Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SAVA or ATNM?
Cassava Sciences, Inc.
(SAVA) is the more profitable company, earning 0. 0% net margin versus -384. 4% for Actinium Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SAVA leads at 0. 0% versus -414. 9% for ATNM. At the gross margin level — before operating expenses — SAVA leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SAVA or ATNM?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SAVA or ATNM better for a retirement portfolio?
For long-horizon retirement investors, Actinium Pharmaceuticals, Inc.
(ATNM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Cassava Sciences, Inc. (SAVA) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ATNM: -97. 7%, SAVA: -19. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SAVA and ATNM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.